Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill.

The American Diabetes Association®'s Obesity Association™ recently published new standards of care, which discourage the use of compounded GLP-1s due to safety, quality, and effectiveness concerns. 

• No comments yet. Be the first to comment!